Litcius/Paper detail

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Koichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, Toshifumi Hibi∥, Satoshi Motoya, Atsuo Maemoto, Mikihiro Fujiya, Toshifumi Ashida, Mitsuru Goto, Takayuki Matsumoto, Yasuo Suzuki, Yukihiro Hamahata, Tomoo Nakagawa, Naoya Kato, Jun Kato, Yutaka Endo, Ryoichi Suzuki, Koichiro Matsuda, Naoki Ohmiya, Shinji Katsushima, Shuhei Hosomi, Ken‐ichi Tarumi, Chiyuki Watanabe, Mitsuru Saito, Yuichiro Yokoyama, Tomoki Inaba, Yasuhisa Sakata, Hitoshi Hongo, Tomoyoshi Shibuya, Kazuhiko Kawakami, Yoichi Kakuta, Atsushi Irisawa, Naoki Yoshimura, Katsuyuki Fukuda, Takayuki Shirai, Hitoshi Ichikawa, Junko Nagata, Takayoshi Suzuki, Kaoru Yokoyama, Takashi Tomidokoro, Yuichiro Kojima, Masahiro Yamada, Hideko Yamamoto, Takayuki Yamamoto, Noriyuki Horiki, Hirozumi Obata, Satoko Inoue, Shinji Tanaka, Tatsuya Toyokawa, Masaki Kunihiro, Takashi Hisabe, Shinichi Ogata, Fuminao Takeshima, Kayoko Matsushima, Nobuyuki Matsuhashi, Hirotake Sakuraba, Masahiro Iwabuchi, Akihiko Tsuchiya, Kan Uchiyama, Takanori Kanai∥, Masanao Nakamura, Tadashi Yokoyama, Nobuyuki Hida, Keiichi Mitsuyama, Taro Osada, Sakiko Hiraoka, Tomoyuki Tsuzuki, Takashige Masuo, Ryota Hokari, Taku Kobayashi, Masayuki Saruta, Masao Araki, Hiroshi Araki, Masahito Shimizu, Masakazu Kikuchi, Takahiro Nishikawa, Hidetoshi Takedatsu, Kunihiko Aoyagi, Toshiaki Ochiai, Nobuo Toda, Yuji Mizokami, Masakazu Nagahori, Kazuhiro Matsueda, Hitoshi Kino, Akira Kanamori, Tsunehiro Suzuki, Toshiharu Sakurai, Masatoshi Kudo

2022˜The œLancet. Gastroenterology & hepatology80 citationsDOI

Topics & Concepts

MedicineUlcerative colitisPlaceboClinical endpointInternal medicineMesalazineIntention-to-treat analysisClinical trialGastroenterologyRandomized controlled trialSurgeryDiseasePathologyAlternative medicineInflammatory Bowel DiseaseCell Adhesion Molecules ResearchNeutrophil, Myeloperoxidase and Oxidative Mechanisms
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study | Litcius